The third largest holder is Meditor Group Ltd, which now holds $500.89 million worth of this stock and that ownership represents almost 5.88% of its market capitalization. The company realized a rise in short interest of 8.25% as of September 29, 2017 from the last reporting period. The stock was sold at an average price of $27.68, for a total transaction of $5,536,000.00.
EXEL has been the topic of a number of other research reports. First Quadrant L P CA bought a new stake in shares of Exelixis in the second quarter worth $144,000. Meeder Asset Management Inc. raised its position in shares of Exelixis by 26.6% during the 2nd quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Exelixis by 1,923.7% during the second quarter. Caxton Associates LP purchased a new stake in Exelixis during the second quarter valued at about $227,000.
Institutions own 81.00% of Exelixis, Inc. If you are viewing this report on another domain, it was illegally stolen and republished in violation of U.S. & global trademark & copyright laws.
Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors sparking the stock on an nearly 30% upturn.
EXEL has been the subject of several analyst reports. The insider now holds 140,000 shares of Exelixis, Inc. Finally, Stifel Nicolaus reissued a "hold" rating and issued a $26.00 price target on shares of Exelixis in a research note on Thursday, August 3rd.
The price target set for the stock is $28.00 and this sets up an interesting set of potential movement for the stock, according to data from Finviz's Research.
Overall, 3 research analysts have assigned a Hold rating and 6 research analysts have given a Buy rating to the stock.Читайте также: Restasis Drugs Held Invalid as Obvious by Eastern District Court of Texas
10/16/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
Exelixis (EXEL) traded up 3.38% during midday trading on Monday, reaching $30.00.
The company is trading down from yesterday's close of 29.02. Fmr Llc owns $1.08 billion in Exelixis, Inc., which represents roughly 12.71% of the company's market cap and approximately 18.53% of the institutional ownership. The stock has more than doubled year-over-year, and capped off today's early gains by touching a new 17-year high of $32.33.
The most recent open market insider trade was Sell of 33,334 shares on a day where the closing price was 23.74.
According to Exelixis, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 80.34%. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The company beat the analyst EPS Estimate with the difference of $0.08. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. The firm's quarterly revenue was up 173.1% on a year-over-year basis. Analysts expect that Exelixis will post $0.27 EPS for the current fiscal year. The stock was sold at an average price of $24.28, for a total transaction of $662,892.56. The Director now owns $0 of the stock per the Form 4 SEC filing.
On 9/18/2017 Stelios Papadopoulos, Director, sold 72,210 with an average share price of $27.76 per share and the total transaction amounting to $2,004,549.60. Gisela Schwab, Pres Prod Dev & Med Aff & CMO disclosed the sale of 100,000 shares of (EXEL). Over the last 90 days, insiders have sold 970,152 shares of company stock valued at $25,923,457. On the other hand, company insiders are holding 1.00%.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2018 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог